PHIO PHARMACEUTICALS CORP. Debt Conversion, Original Debt, Amount
PHIO PHARMACEUTICALS CORP. (PHIO) reported Debt Conversion, Original Debt, Amount of $1.03 million for the 1-month period ending 2012-04-30, per its 10-Q filed 2012-08-14.
Discontinued › Cash Flow › Financing Activities
us-gaap:DebtConversionOriginalDebtAmount1 · last filed 2013-03-29
- 2012-04-30: Debt Conversion, Original Debt, Amount 1 month $1.03M.
- 2012-04-27: Debt Conversion, Original Debt, Amount 1 month $1.00M; Debt Conversion, Original Debt, Amount 1 month as first filed $1.03M.
| Period end | Debt Conversion, Original Debt, Amount 1 month | Debt Conversion, Original Debt, Amount 1 month as first filed |
|---|---|---|
| 2012-04-30 | $1.03M 10-Q · filed 2012-08-14 | |
| 2012-04-27 | $1.00M 10-K · filed 2013-03-29 | $1.03M 10-Q · filed 2012-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |